4-(3-Phenylsulfonylamino-5-trifluoromethylpyridine-2-yloxymethyl)benzoic Acid | 209687-70-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-Phenylsulfonylamino-5-trifluoromethylpyridine-2-yloxymethyl)benzoic Acid
• 英文别名: 4-[[3-(Benzenesulfonamido)-5-(trifluoromethyl)pyridin-2-yl]oxymethyl]benzoic acid
• CAS: 209687-70-7
• 化学式: C₂₀H₁₅F₃N₂O₅S
• 分子量: 452.411
• InChiKey: ZFLPHXLNVWIMFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  methyl 4-(3-nitro-5-trifluoromethylpyridine-2-yloxymethyl)benzoate 生成 4-(3-Phenylsulfonylamino-5-trifluoromethylpyridine-2-yloxymethyl)benzoic Acid
  参考文献：
  名称：

  Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient

  摘要：

  化合物的结构式（I）的磺胺基或碳酰胺衍生物及其作为活性成分的药物组合物：（其中A环，B环是碳环，杂环；Z1是—COR1，—CH═CH—COR1等；Z2是H，烷基等；Z3是单键，烷基；Z4是SO2，CO；Z5是烷基，苯基，杂环等；R2是CONR8，O，S，NZ6，Z7-烷基，烷基等；R3是H，烷基，卤素，CF3等；R4是H，（取代）烷基等；n，t为1-4）。结构式（I）的化合物可以结合到PGE2的受体上，并显示对其作用的拮抗活性或激动活性。因此，它们被认为在抑制子宫收缩、镇痛剂、止泻药、催眠剂、增加膀胱容量的药物、子宫收缩药物、通便剂、抑制胃酸分泌、降压或利尿剂方面是有用的。

  公开号：

  US06448290B1

文献信息

• Chemokine Receptor Antagonist and Medical Use Thereof
  申请人：Habashita Hiromu

  公开号：US20070254886A1

  公开（公告）日：2007-11-01

  The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.

  本发明涉及一种由公式（I）表示的化合物，其盐、N-氧化物、溶剂化物或前药，以及其医药用途（公式中的符号如说明书所述）。公式（I）表示的化合物具有趋化因子受体（尤其是在CCR4和/或CCR5中）拮抗活性。因此，它对于预防和/或治疗趋化因子受体介导的疾病，如炎症和/或过敏性疾病[全身性炎症反应综合征（SIRS）、过敏性休克、过敏性反应、过敏性血管炎、移植排斥反应、肝炎、肾炎、肾病、胰腺炎、鼻炎、关节炎、炎症性眼部疾病、炎症性肠病、脑和/或循环系统疾病、呼吸系统疾病、皮肤病、自身免疫性疾病等]、感染[病毒性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合征、SARS等）等]等非常有用。
• CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF
  申请人：HABASHITA Hiromu

  公开号：US20100266539A1

  公开（公告）日：2010-10-21

  The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.

  本发明涉及一种由式（I）所表示的化合物，其盐、N-氧化物、溶剂化物或前药，以及其医药用途（式中符号如规范所述）。由式（I）所表示的化合物具有趋化因子受体（特别是在CCR4和/或CCR5中）的拮抗活性。因此，它对于预防和/或治疗趋化因子受体介导的疾病，如炎症和/或过敏性疾病[全身性炎症反应综合征（SIRS）、过敏反应、过敏性血管炎、移植排斥反应、肝炎、肾炎、肾病、胰腺炎、鼻炎、关节炎、炎症性眼病、炎症性肠病、脑和/或循环系统疾病、呼吸道疾病、皮肤病、自身免疫性疾病等]、感染[病毒性疾病（人类免疫缺陷病毒感染、获得性免疫缺陷综合征、SARS等）等]等具有用处。
• SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0947500A1

  公开（公告）日：1999-10-06

  The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is -COR1, -CH=CH-COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4). The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

  式(I)的磺酰胺或羧酰胺衍生物以及包含它们作为活性成分的药物组合物： (其中 A 环、B 环为碳环、杂环；Z1 为-COR1、-CH=CH-COR1 等；Z2 为 H、烷基等；Z3 为单键、亚烷基；Z4 为 SO2、CO；Z5 为烷基、苯基、杂环等。R2 是 CONR8、O、S、NZ6、Z7-烷基、亚烷基等；R3 是 H、烷基、卤素、CF3 等；R4 是 H、（取代的）烷基等；n、t 是 1-4）。 式（I）化合物可与 PGE2 受体结合，并显示出对其作用的拮抗活性或激动活性。因此，它们被认为可用作抑制子宫收缩的药物、镇痛药、止泻药、睡眠诱导剂、增加膀胱容量的药物或子宫收缩的药物、泻药、抑制胃酸分泌的药物、降压药或利尿剂。
• US6448290B1
  申请人：——

  公开号：US6448290B1

  公开（公告）日：2002-09-10
• US6790866B2
  申请人：——

  公开号：US6790866B2

  公开（公告）日：2004-09-14